ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City. RxSight’s management is scheduled to present on Wednesday, December 3, 2025, at 12:00 p.m. Eastern Time. A live and archived webcast of the presentation wi ...

Core Insights - RxSight, Inc. reported a quarterly loss of $0.04 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of +78.95% [1] - The company generated revenues of $30.34 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 19.02%, although this represents a decline from $35.31 million in the same quarter last year [2] - RxSight shares have declined approximately 73.8% year-to-date, contrasting with a 15.1% gain in the S&P 500 [3] Earnings Outlook - The earnings outlook for RxSight is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.15 on revenues of $28.68 million, and -$0.56 on revenues of $125.7 million for the current fiscal year [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which RxSight belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - RxSight generated third-quarter revenue of $30.3 million, down 14% compared to $35.3 million in the year-ago quarter, and down 10% compared to $33.6 million in the second quarter of 2025 [8] - GAAP net loss in the third quarter of 2025 was $9.8 million, or a loss of $0.24 per share, compared to a GAAP net loss of $6.3 million, or $0.16 per share in the third quarter of 2024 [11] - Gross margin in the third quarter of 2025 was 79.9%, an increase from 71.4% in the year-ago period [9] Business Line Data and Key Metrics Changes - Sold 26,045 Light Adjustable Lenses (LALs), generating $25.7 million in LAL revenue, up 6% compared to the third quarter of 2024 [8] - Sold 25 Light Delivery Devices (LDDs) in the quarter, down 68% from 78 units in the prior year period [8] - LAL revenue represented 85% of total revenue in the third quarter, an increase from 69% in the third quarter of 2024 [8] Market Data and Key Metrics Changes - Approximately 1,100 LDDs are in the field, representing a 25% increase year-over-year [9] - More than 2,000 ophthalmologists implanted the LAL, representing roughly one-fifth of the estimated total number of U.S. cataract surgeons [4] Company Strategy and Development Direction - The company is focusing on strengthening commercial execution in the U.S. while laying groundwork for global growth, particularly in Asia and Europe [4][5] - New practice development and clinical engagement programs have been launched to optimize LAL workflow and enhance clinical confidence [4] - The company aims to strategically expand its base of LDDs and implanting surgeons while positioning customers for sustained growth [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in building a strong foundation for future growth despite challenges, including a decline in Medicare's physician fee for cataract surgery [16] - The company is narrowing its full-year 2025 revenue guidance to $125 million-$130 million, implying a year-over-year decline of 11%-7% [12] - Management anticipates continued interest in premium IOL options, particularly the LAL, as practices adapt to changing reimbursement rates [16] Other Important Information - SG&A expenses in the third quarter of 2025 were $27.3 million, a 7% increase year-over-year, primarily due to rising personnel costs [10] - R&D expenses rose 3% to $9.1 million compared to the third quarter of 2024 [10] Q&A Session Summary Question: What metrics will be used to evaluate the changes being implemented? - The key metric is the number of LAL procedures, along with the number of physicians implanting each quarter [20][21] Question: How will new entrants in the market impact demand for LAL? - Lower reimbursement for traditional cataract surgery is expected to be a tailwind for premium IOLs, with modest long-term impact from new entrants [22][23] Question: What is driving the increase in active surgeons? - The increase is attributed to new LDD sales and existing practices adopting LAL procedures [27][28] Question: What is the outlook for 2026? - While specific guidance for 2026 is not provided, management expects sequential growth in LAL procedures [36] Question: How does the company view the health of the underlying IOL market? - The premium segment is expected to remain strong, while the monofocal segment may be more affected by economic pressures [42] Question: What is the potential for LALs in post-refractive patients? - Post-refractive cases represent 10%-20% of the patient population, indicating a significant opportunity [52][54] Question: How does the company view its penetration in practices? - Some practices have already achieved standard of care with LALs, and the company aims to deepen its presence in existing accounts [57][58]

Sales Performance - The installed base of Light Delivery Devices (LDDs) reached 1,109 as of September 30, 2025, an increase from 888 at the same time in 2024, representing a growth of approximately 25%[107] - For the quarter ended September 30, 2025, the company sold 25 LDDs, a decrease of 53 units compared to the same period in 2024, indicating slower adoption of the RxSight technology[112] - LAL sales increased by 1,491 units year-over-year for the quarter ended September 30, 2025, totaling 26,045 units sold, primarily due to a larger LDD installed base[112] - Total sales for the three months ended September 30, 2025, were $30.34 million, a decrease from $35.31 million in the same period in 2024, reflecting a decline of approximately 14%[118] - Revenue from LALs for the three months ended September 30, 2025, was $25.69 million, compared to $24.23 million in 2024, marking an increase of about 6%[118] - Sales decreased by $5.0 million, or 14.1%, to $30.3 million for the three months ended September 30, 2025, primarily due to a 68% reduction in LDD sales[131] - For the nine months ended September 30, 2025, sales increased by $2.2 million, or 2.2%, to $101.9 million, driven by increased LAL sales[137] Financial Performance - The company expects to incur net losses and negative cash flows from operations in the near future due to increased costs associated with being a public company[110] - Net loss for the three months ended September 30, 2025, was $9.8 million, a 54.9% increase compared to the net loss of $6.3 million for the same period in 2024[131] - For the nine months ended September 30, 2025, net cash used in operating activities was $14.4 million, compared to $12.7 million for the same period in 2024, reflecting a net loss of $29.8 million in 2025 versus $21.5 million in 2024[150][151] - Net cash provided by financing activities for the nine months ended September 30, 2025, was $0.8 million, significantly lower than $120.3 million in 2024, which included proceeds from a public offering of $108.1 million[155][156] Cost and Expenses - SG&A expenses increased by $1.7 million, or 6.8%, to $27.3 million for the three months ended September 30, 2025, mainly due to increased selling and marketing costs[133] - Research and development expenses rose by $0.2 million, or 2.5%, to $9.0 million for the three months ended September 30, 2025, primarily due to increased overhead costs[134] - SG&A expenses for the nine months ended September 30, 2025, increased by $11.7 million, or 16.0%, to $85.0 million, largely due to higher selling and marketing costs[140] - Research and development expenses for the nine months ended September 30, 2025, increased by $4.5 million, or 17.8%, to $29.6 million, mainly due to increased personnel costs[141] Cash and Investments - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments of $227.5 million, with an accumulated deficit of $651.9 million[144] - Net cash provided by investing activities for the nine months ended September 30, 2025, was $26.5 million, primarily from net maturities of short-term investments of $29.2 million, while in 2024, net cash used was $100.6 million due to net purchases of short-term investments of $96.0 million[153][154] - As of September 30, 2025, the company had cash and cash equivalents and short-term investments totaling $227.5 million, with $197.9 million in highly liquid money market and U.S. Treasury securities[165] Operational Strategy - The company plans to continue significant investments in sales, marketing, and research and development to drive adoption and enhance product offerings[110] - Research and development activities are focused on improving the RxSight system and expanding its indications, with potential future acquisitions to complement the product portfolio[109] - The company has integrated its clinical and sales teams into a unified Customer Success Organization to enhance customer experience and support long-term growth[108] - The company is focused on retaining current employees and hiring additional personnel, which may impact future operational capabilities[152] Market Conditions - The company is facing supply chain constraints and inflation, which may impact its ability to manufacture current and new products, potentially affecting financial condition and results of operations[162] - Uncertain macroeconomic conditions, including inflationary pressures and tariffs, may negatively impact the company's financial results and liquidity through 2025 and beyond[163] - The company does not have material exposure to changes in the fair value of cash and cash equivalents and short-term investments due to their short-term nature, with a hypothetical 1.00% change in interest rates not materially affecting interest income[165] - The company has de minimis amounts of revenue and expenses denominated in currencies other than U.S. dollars, indicating limited foreign currency exchange risk[166] - The gross margin is expected to fluctuate based on production volumes and manufacturing costs, with higher margins anticipated as LAL production increases[121] - Gross margin increased to 79.9% for the three months ended September 30, 2025, compared to 71.4% for the same period in 2024, driven by a higher percentage of revenue from LAL sales[132] - Gross margin for the nine months ended September 30, 2025, improved to 76.3% from 70.4% in the same period of 2024, attributed to a favorable product mix[138]

Core Insights - RxSight, Inc. reported a total revenue of $30.3 million for Q3 2025, a decrease of 14% compared to $35.3 million in Q3 2024, with a notable increase in Light Adjustable Lens (LAL) revenue by 6% and a significant decrease in Light Delivery Device (LDD) revenue by 69% [5][9] - The company experienced a net loss of $(9.8) million, or $(0.24) per share, compared to a net loss of $(6.3) million, or $(0.16) per share in the same quarter of the previous year [8][9] - Gross profit for Q3 2025 was $24.2 million, representing 80% of revenue, an increase from 71% in Q3 2024, primarily due to a favorable product mix shift towards LAL sales [6][9] Financial Highlights - Total revenue for Q3 2025 was $30.3 million, down 14% from $35.3 million in Q3 2024 [5][9] - Gross profit was $24.2 million, or 80% of revenue, compared to $25.2 million, or 71% of revenue in Q3 2024 [6][9] - Operating expenses increased by 6% to $36.4 million from $34.4 million in Q3 2024, reflecting ongoing investments in LAL sales and R&D [7][9] - The company reported an adjusted net loss of $(1.7) million, or $(0.04) per share, compared to an adjusted net gain of $0.2 million, or $0.01 per share in Q3 2024 [8][9] Strategic Highlights - The company noted a stabilization and recovery in procedure trends, with increased engagement from surgeons observed at major ophthalmic conferences [4] - RxSight has realigned its U.S. commercial organization to enhance customer relationships and drive growth in LAL procedures [9] - The company launched new practice development and clinical engagement programs aimed at sharing insights from over 250,000 LAL cases [9] Guidance - The company narrowed its full-year 2025 revenue guidance to a range of $125.0 million to $130.0 million, reflecting an implied decrease of 11% to 7% compared to 2024 [14] - Gross margin guidance was raised to a range of 76% to 77%, an increase from the previous range of 72% to 74% [14] - Operating expenses are projected to remain between $145.0 million and $155.0 million, indicating an implied increase of 7% to 14% compared to 2024 [14]

Core Viewpoint - RxSight, Inc. will report its financial results for Q3 2025 on November 5, 2025, with a conference call scheduled for 1:30 p.m. Pacific Time [1] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices aimed at providing customized vision for patients post-cataract surgery [3] - The company offers the RxSight® Light Adjustable Lens system, which is the first and only commercially available intraocular lens technology that can be adjusted after surgery [3] - This technology allows doctors to tailor and enhance the quality of vision for patients following cataract procedures [3] Conference Call Details - The conference call to discuss the financial results can be accessed by dialing (800) 715-9871 or (646) 307-1963, with the conference code: 6619966 [2] - The call will also be available in listen-only mode via the company's investor relations website [2] - An archived recording of the call will be accessible shortly after its conclusion [2]

Core Insights - RxSight, Inc. will participate in the American Academy of Ophthalmology Annual Meeting (AAO 2025) with multiple Live Learning Sessions showcasing the Light Adjustable Lens technology [1][2] Company Overview - RxSight, Inc. specializes in ophthalmic medical devices aimed at providing customized vision solutions for patients post-cataract surgery [5] - The RxSight Light Adjustable Lens system is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing for personalized vision correction [5] Live Learning Sessions Details - The sessions will feature insights from leading surgeons on the clinical advantages and economic impact of the Light Adjustable Lens [2] - A schedule of sessions includes topics such as ROI, career development, clinical confidence, and patient-centered outcomes, with various experts presenting on October 18 and 19 [3][4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against RxSight, Inc. following a class action lawsuit that alleges the company made false statements and failed to disclose significant issues affecting its sales and financial guidance [1][6]. Summary by Sections Company Overview - RxSight, Inc. is facing a class action lawsuit filed on July 22, 2025, with a class period from November 7, 2024, to July 8, 2025, concerning alleged breaches of fiduciary duties by its board of directors [1]. Allegations - The lawsuit claims that RxSight experienced "adoption challenges" and structural issues leading to declines in sales and utilization of its products [6]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [6]. Financial Impact - On July 8, 2025, RxSight reported preliminary second-quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [6]. - The company lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint, and the CEO attributed the sales stall to adoption challenges [6]. - Following this announcement, RxSight's stock price fell nearly 38% [6].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud affecting investors between May 7, 2024, and July 8, 2025 [1][2] Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2] - It is alleged that the defendants overstated the demand for RxSight's products [2] - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2] - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - RxSight, Inc. is under investigation for potential claims related to a federal securities class action, with a deadline for investors to seek lead plaintiff status set for September 22, 2025 [1] Group 1 - Faruqi & Faruqi, LLP, a prominent national securities law firm, is leading the investigation into RxSight, Inc. [1] - The investigation pertains to potential claims against RxSight, which trades on NASDAQ under the ticker RXST [1] - The firm has multiple offices across the United States, including locations in New York, Pennsylvania, California, and Georgia [1]